50 results about "Neuronal disease" patented technology

Methods, systems, and techniques for controlling actuators by using eye gaze technology such as in a wheelchair or bed, are provided. Example embodiments provide an Eye Gaze Actuator Control System (“EGACS”) which enables people with advanced motor neuron diseases or disabilities like amyotrophic lateral sclerosis or muscular dystrophy to use eye gaze technologies to control their actuators that control seating, bed positioning, and movement of motor-controlled devices. In one embodiment, the example EGACS comprises a display device, eye gaze sensor, eye gaze control application, and device interface(s) to one or more other devices that control aspects of a powered wheelchair, bed, vehicle, or other device. These components cooperate to control the powered wheelchair, bed, or vehicle using eye gaze technology as opposed to by manual control.

A combined neuromodulation and / or neurostimulation system for mitigating locomotor deficits of / or neuronal disorders, especially Parkinson's disease, said system comprises: at least one Deep Brain Stimulation System for providing Deep Brain Stimulation to brain tissue of a subject, at least one control unit, configured and adapted to provide stimulation data, at least one stimulation unit, operatively connected to the at least one control unit, the at least one stimulation unit being configured and adapted to deliver epidural electrical stimulation to the dorsal side of the spinal cord of said subject, and at least one implantable pulse generator, wherein the at least one stimulation unit includes one or more electrodes configured to be implanted epidurally, the one or more electrodes being operatively connected to the at least one IPG.

The present invention refers to a method for producing a polymer in form of a gel or a particle, and to the resulting polymer, gel and particle, respectively. The polymer comprises a carbon donor and a metal oxide precursor, a metal oxide or a combination thereof and optionally an active agent. The invention is further directed to a composition and film comprising such polymer, and their use as a medicament for example in treating diabetes, obesity, neuronal disease, viral infection or cancer.

The present invention relates to salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharma-ceutically acceptable solvates thereof for use in the treatment and / or prevention of sensory neuron diseases.

The present invention relates to sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof, for use in the treatment and / or prevention of motor neuron diseases and neuromuscular junction disorders.

Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as “c-Abl”). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and / or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.

Disclosed are compositions and / or methods of use of the compositions for patients with neuronal diseases such as AD, Parkinson's, Huntington's, multiple sclerosis, and ALS. In certain embodiments flavonoids alone, or in a pharmaceutical preparation, are administered through the nasal olfactory route. In certain embodiments the flavonoid is apigenin and the neural disease is Alzheimer's. In some embodiments a porosome complex is administered for reconstitution into a neural cell. In certain embodiments, a co-administered blood-brain barrier traversing peptide is configured as a mimic of a domain of ATP 1 A3 and / or Tubulin.

Antibodies that specifically bind to TrkB and methods for using the same are described. Neuroprotective agonist antibodies are described, as indicated by their effect on enhancing the survival of retinal ganglion cells in vitro, and these agonist antibodies may be used to treat eye disorders, such as glaucoma. Additionally, other neuronal diseases or disorders, including those characterized by partial neuronal damage, benefit from treatment using these agonist antibodies. In certain embodiments, the present invention comprises antibodies that bind to TrkB and mediate cell signaling. The antibodies of the present invention may be whole human, non-natural antibodies formulated as injectable excipients.

As a result of performing an analysis exclusively on lower limb type and upper limb type ALS, excluding the bulbar palsy type ALS, among ALS for which it had been considered in existing reports that a reduction in Crtac1B was not observed, a significant correlation between the prognosis and the Crtac1B concentration in the cerebrospinal fluid was observed. Thus, it was discovered that Crtac1B is useful as a biomarker for predicting the prognosis of lower limb type and upper limb type ALS. As a result of analyzing the association between the motor function and the Crtac1B concentration in the cerebrospinal fluid before and after treatment in SMA patients treated with an SMA therapeutic agent, it was found that the Crtac1B concentration in the cerebrospinal fluid reflects the disease progression of SMA, and that Crtac1B is useful as a biomarker for diagnosing the therapeutic effect by the SMA therapeutic agent.

Antibodies that specifically bind to TrkB and methods of use thereof are disclosed. Agonist antibodies having neuroprotective effects, as shown by their ability to enhance retinal ganglion cell survival in vitro, are disclosed, and these agonist antibodies can be used in the treatment of conditions such as eye diseases, including glaucoma. In addition, other neuronal diseases or conditions can also benefit from treatment with these agonist antibodies, including those characterized in part by neuronal damage. In certain embodiments, the present invention includes antibodies that bind to TrkB and mediate cell signaling. The antibodies of the present invention can be fully human, non-naturally occurring antibodies formulated with an excipient for injection.

A method for treating a patient suffering from a neuronal hypo-kinetic disease or a neuronal hyper-kinetic disease by modulating neuronal activity in the: internal globus pallidus (GPi), in the anterior motor thalamus and / or in the external globus pallidum (GPe) and / or in the subthalamic nucleus (STN) by utilizing suppressor and / or enhancer DREADDs is provided.

Methods, systems, and techniques for controlling posture by using eye gaze technology to facilitate position changes in seating, such as in a wheelchair or bed, are provided. Example embodiments provide an Eye Gaze Posture Control System (“EGPCS”) which enables people with advanced motor neuron diseases or disabilities like amyotrophic lateral sclerosis or muscular dystrophy to use eye gaze technologies to control their seating and bed positioning. In one embodiment, the example EGPCS comprises a posture and pressure advisor, logging and telemetry logic, a posture control application, device interface(s) to one or more other devices that control aspects of the powered wheelchair or bed, and eye gaze actuation control. These components cooperate to adjust position of a seat or a bed using eye gaze technology as opposed to by a virtual cursor or by manual control.

Presented herein are methods of identifying a subject who has, or is at risk of developing a motor neuron disease, specifically Amyotrophic Lateral Sclerosis (ALS), and / or Primary Lateral Sclerosis (PLS), that includes determining a presence or amount of two or more micro-RNAs (miRNAs) selected from miR-199a-3p, miR-4454, miR-10b-5p, miR-151a-5p, miR-199a-5p, miR-151a-3p, miR-146a-5p, and / or miR-29b-3p in a subject's circulating blood, without determining a presence or amount of the miRNAs from neural-derived exosomes. Also presented herein are methods of preventing, treating, or delaying the onset of a motor neuron disease, specifically ALS and / or PLS.

The present invention relates to multifunctional agents as defined in the claims based on N-substituted 1,4-benzothiazepines with cyclopropanol groups and their "open" analogues (such as the 3-[(4-methoxyphenyl)oxy]- and 3-[(4-methoxyphenyl)thio]propane-1-amine cyclopropanol derivatives; see formulae below) as well as the rearrangement products obtained from such cyclopropanol compounds, i.e. ethyl ketones, and the oxidation products from such cyclopropanol compounds, i.e. oxiranes. Such compounds can be used by preventing Ca2+ leak through ryanodine receptor 2 (RyR2) and enhance cardiac sarco-endoplasmic reticulum (SR) Ca2+ load by activation of Ca2+-dependent ATPase 2a (SERCA2a) for example for the treatment of cardiac or neuronal diseases.

The invention relates inter alia to a protein which is a VTFT isoform of a BPIFB4 protein or a functional fragment thereof for use in the treatment or prophylaxis of a condition selected from neuronal diseases and injuries, said diseases and injuries being associated with mitochondrial dysfunction and / or protein aggregation and / or ameliorated by CXCR4 activation.

The present invention relates to a method for identifying and detecting the expression of biomarkers present in choroidal and retinal pigmented epithelium disorders or in ocular angiogenic, epithelial and neuronal disorders. The invention further encompasses a kit for biomarker identification and uses thereof. The present invention pertains to the field of chemical biology, more specifically in the healthcare sector, and describes a method for identifying and detecting the expression of a set of biomarkers present in severe ophthalmological diseases.

To provide solid forms of promoter of spinogenesis.SOLUTION: There are provided herein crystalline forms of 2-(2-(2-(2-(4-(benzo[d]thiazol-2-yl)phenoxy)ethoxy)ethoxy)ethoxy)ethan-1-ol (Compound I). There are also provided processes of manufacturing the crystalline forms and methods of using the crystalline forms. The present disclosure provides forms of Compound I and salts, co-crystals, hydrates, and solvates thereof. There are also described herein processes for making the forms of Compound I, pharmaceutical compositions comprising crystalline forms of Compound I and methods for using such forms and pharmaceutical compositions in the treatment of diseases responsive to spinogenesis. In some embodiments, the disease is a neuronal disease.SELECTED DRAWING: None

Aspects of the present disclosure relate to methods and compositions relating to the selection and expansion of immune cells, including T cells expressing CD16Hi in combination with a V [delta] 2 T cell receptor. The T cells generated by the methods disclosed herein are suitable for allogeneic cell therapy as they do not induce graft versus host disease (GvHD) and resist host immune allogeneic rejection. Thus, such cells are suitable for ready-to-use in clinical therapy for diseases such as cancer, infectious diseases, autoimmune diseases, heart diseases and neuronal diseases.

Disclosed herein are compound embodiments that are useful for treating a variety of diseases, particularly neurological diseases, motor neuron diseases, copper deficiency-related diseases, and / or mitochondrial deficiencies. The compound embodiments described herein also can be used in PET methods. Also disclosed herein are embodiments of methods of making and using the compound embodiments, as well as pharmaceutical formulations comprising the disclosed compound embodiments.

The present invention relates to the succinate salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharma- ceutically acceptable solvates thereof for use in the treatment and / or prevention of motor neuron diseases and neuromuscular junction disorders.

The various embodiments relate to peptide antagonists of yc-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21). The yc-cytokines are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of yc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting yc-cytokine activity involve raising neutralizing antibodies against each individual yc-cytokine family member / receptor subunit. However, success has been limited and often multiple yc-cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus yc-subunit binding site to inhibit yc-cytokine activity. Such approach allows for flexibility in antagonist design. In several embodiments, peptides exhibit Simul-Block activity, inhibiting the activity of multiple yc-cytokine family members.

Disclosed are compositions and / or methods of use of the compositions for patients with neuronal diseases such as AD, Parkinson's, Huntington's, multiple sclerosis, and ALS. In certain embodiments flavonoids alone, or in a pharmaceutical preparation, are administered through the nasal olfactory route. In certain embodiments the flavonoid is apigenin and the neural disease is Alzheimer's. In some embodiments a porosome complex is administered for reconstitution into a neural cell. In certain embodiments, a co-administered blood-brain barrier traversing peptide is configured as a mimic of a domain of ATP1A3 and / or Tubulin.

Provided herein are methods and compositions related to treating motor neuron diseases, such as ALS, in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside, pterostilbene and a phosphodiesterase (PDE) inhibitor, including a PDE4 inhibitor such as ibudilast, and also including a thiol / cysteine donor, such as acetylcysteine.

Disclosed are compositions and / or methods of use of the compositions for patients with neuronal diseases such as AD, Parkinson's, Huntington's, multiple sclerosis, and ALS. In certain embodiments flavonoids alone, or in a pharmaceutical preparation, are administered through the nasal olfactory route. In certain embodiments the flavonoid is apigenin and the neural disease is Alzheimer's. Targeted dosages may affect mitochondrial function in brain neural cells thus ameliorating a neural disease. In some embodiments a porosome complex is administered for reconstitution into a neural cell. In certain embodiments, one or more macrocyclic or linear peptides are administered.

Presented herein are methods of identifying a subject who has, or is at risk of developing a motor neuron disease, specifically Amyotrophic Lateral Sclerosis (ALS), and / or Primary Lateral Sclerosis (PLS), that includes determining a presence or amount of two or more micro-RNAs (miRNAs) selected from miR-199a-3p, miR-4454, miR-10b-5p, miR-151a-5p, miR-199a-5p, miR-151a-3p, miR-146a-5p, and / or miR-29b-3p in a subject's circulating blood, without determining a presence or amount of the miRNAs from neural-derived exosomes. Also presented herein are methods of preventing, treating, or delaying the onset of a motor neuron disease, specifically ALS and / or PLS.

The present application relates to pyrimidopyridone and pteridone compounds of Formula I, to processes for their preparation and to compositions comprising them More particularly, the present application relates to compound of Formula I that have activity as inhibitors of the general control nonderepressible 2 (GCN2) kinase and to their use in the treatment of diseases, disorders or conditions treatable by inhibiting GCN2 kinase such as cancers and neuronal diseases.

The invention relates to prebiotics, and their use in treating, preventing or ameliorating psychiatric disorders, improving neurotransmission, improving emotional well-being and / or improving sleep. The invention also relates to a method of treating, preventing or ameliorating psychiatric disorders, improving neurotransmission, improving emotional well-being and / or improving sleep, by administering a prebiotic to a subject.

The instant invention provides methods and compositions related to discovery of Free Fatty Acid Receptor 1 (FFA1) as a therapeutic target for treatment or prevention of diseases or disorders of neurons that are characterized by angiogenesis, or of vascular diseases of the eye, retinal degeneration and / or tumors more generally. Therapeutic and / or prophylactic uses and compositions of known FFA1 inhibitors, including small molecules and nucleic acid agents, are described. Methods for identification of novel FFA1 inhibitors are also provided.

Disclosed are compositions and / or methods of use of the compositions for patients with neuronal diseases such as AD, Parkinson's, Huntington's, multiple sclerosis, and ALS. In certain embodiments flavonoids alone, or in a pharmaceutical preparation, are administered through the nasal olfactory route. In certain embodiments the flavonoid is apigenin and the neural disease is Alzheimer's. Targeted dosages may affect mitochondrial function in brain neural cells thus ameliorating a neural disease. In some embodiments a porosome complex is administered for reconstitution into a neural cell. In certain embodiments, one or more macrocyclic or linear peptides are administered.

Provided is a pharmaceutical composition for preventing or treating neuronal diseases comprising, as an active ingredient, an exon 2-deleted AIMP2 variant (AIMP2-DX2) gene or a vector comprising the gene, and a method for treating neuronal diseases in animals other than humans, comprising administering the same to a subject in need of treatment. The pharmaceutical composition comprising, as an active ingredient, a AIMP2-DX2 gene or a vector comprising the gene has the effects of apoptosis inhibition, dyskinesia amelioration and oxidative stress inhibition and thus can be widely used for preventing and treating neuronal diseases such as Parkinson's disease and amyotrophic lateral sclerosis.